198 related articles for article (PubMed ID: 35561634)
1. Formulation optimization, in vitro and in vivo evaluation of agomelatine-loaded nanostructured lipid carriers for augmented antidepressant effects.
Gul M; Shah FA; Sahar NU; Malik I; Din FU; Khan SA; Aman W; Choi HI; Lim CW; Noh HY; Noh JS; Zeb A; Kim JK
Colloids Surf B Biointerfaces; 2022 Aug; 216():112537. PubMed ID: 35561634
[TBL] [Abstract][Full Text] [Related]
2. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
3. Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: Peyer's patch targeting approach.
Prajapati JB; Verma SD; Patel AA
Int J Nanomedicine; 2018; 13(T-NANO 2014 Abstracts):35-38. PubMed ID: 29593392
[TBL] [Abstract][Full Text] [Related]
4. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
5. Levosulpiride-loaded nanostructured lipid carriers for brain delivery with antipsychotic and antidepressant effects.
Maqsood S; Din FU; Khan SU; Elahi E; Ali Z; Jamshaid H; Zeb A; Nadeem T; Ahmed W; Khan S; Choi HG
Life Sci; 2022 Dec; 311(Pt B):121198. PubMed ID: 36396112
[TBL] [Abstract][Full Text] [Related]
6. Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain.
Salunkhe SS; Bhatia NM; Bhatia MS
Drug Deliv; 2016 May; 23(4):1306-16. PubMed ID: 25080227
[TBL] [Abstract][Full Text] [Related]
7. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.
Beg S; Saini S; Bandopadhyay S; Katare OP; Singh B
Drug Dev Ind Pharm; 2018 Mar; 44(3):407-420. PubMed ID: 29048242
[TBL] [Abstract][Full Text] [Related]
8. Nose to Brain Delivery of Astaxanthin-Loaded Nanostructured Lipid Carriers in Rat Model of Alzheimer's Disease: Preparation, in vitro and in vivo Evaluation.
Shehata MK; Ismail AA; Kamel MA
Int J Nanomedicine; 2023; 18():1631-1658. PubMed ID: 37020692
[TBL] [Abstract][Full Text] [Related]
9. Ursolic acid rich Ocimum sanctum L leaf extract loaded nanostructured lipid carriers ameliorate adjuvant induced arthritis in rats by inhibition of COX-1, COX-2, TNF-α and IL-1: Pharmacological and docking studies.
Ahmad A; Abuzinadah MF; Alkreathy HM; Banaganapalli B; Mujeeb M
PLoS One; 2018; 13(3):e0193451. PubMed ID: 29558494
[TBL] [Abstract][Full Text] [Related]
10. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers.
Wang W; Chen L; Huang X; Shao A
AAPS PharmSciTech; 2017 Feb; 18(2):509-516. PubMed ID: 27120090
[TBL] [Abstract][Full Text] [Related]
11. Development of Oral Lipid Based Nano-formulation of Dapagliflozin: Optimization, in vitro Characterization and ex vivo Intestinal Permeation Study.
Zafar A
J Oleo Sci; 2020; 69(11):1389-1401. PubMed ID: 33132278
[TBL] [Abstract][Full Text] [Related]
12. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy.
Jiang H; Pei L; Liu N; Li J; Li Z; Zhang S
Drug Deliv; 2016 May; 23(4):1379-82. PubMed ID: 26162024
[TBL] [Abstract][Full Text] [Related]
13. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
14. Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerative Colitis.
Deng J; Wu Z; Zhao Z; Wu C; Yuan M; Su Z; Wang Y; Wang Z
Int J Nanomedicine; 2020; 15():3937-3951. PubMed ID: 32581538
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity.
Khan N; Shah FA; Rana I; Ansari MM; Din FU; Rizvi SZH; Aman W; Lee GY; Lee ES; Kim JK; Zeb A
Int J Pharm; 2020 Mar; 577():119033. PubMed ID: 31954864
[TBL] [Abstract][Full Text] [Related]
16. Enhanced neuroprotective and antidepressant activity of curcumin-loaded nanostructured lipid carriers in lipopolysaccharide-induced depression and anxiety rat model.
Rubab S; Naeem K; Rana I; Khan N; Afridi M; Ullah I; Shah FA; Sarwar S; Din FU; Choi HI; Lee CH; Lim CW; Alamro AA; Kim JK; Zeb A
Int J Pharm; 2021 Jun; 603():120670. PubMed ID: 33964337
[TBL] [Abstract][Full Text] [Related]
17. Nanostructured lipid carriers for the topical delivery of tretinoin.
Ghate VM; Lewis SA; Prabhu P; Dubey A; Patel N
Eur J Pharm Biopharm; 2016 Nov; 108():253-261. PubMed ID: 27519827
[TBL] [Abstract][Full Text] [Related]
18. Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease.
Sinhmar GK; Shah NN; Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Jul; 44(7):1078-1089. PubMed ID: 29376433
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate.
Abdelbary G; Haider M
Pharm Dev Technol; 2013; 18(5):1159-68. PubMed ID: 21958084
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: In vitro and in vivo anesthesia evaluation.
Yue Y; Zhao D; Yin Q
Biomed Pharmacother; 2018 Feb; 98():813-820. PubMed ID: 29571251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
